NBCA’s Role in Patient Advocacy
“WE KNOW THE PATIENT BECAUSE WE ARE THE PATIENT”
- Promote supportive public and private sector policy.
- Assist in establishing guidelines for the prevention, treatment, and management of blood clots.
- Promote funding for and establishment of comprehensive thrombophilia programs to allow every patient access to thrombosis specialists within a reasonable distance where patients live.
- Assist scientists with research efforts relating to all aspects of thrombosis and thrombophilia.
- Create a national policy agenda and a grassroots advocacy network.
Take Action to Help Stop the Clot®
Did you know there is little federal funding for blood clot education and awareness efforts in the United States? Think your voice does not matter? Think otherwise! Help the National Blood Clot Alliance advocate for additional funding from U.S. Congress for an expansion of educational and awareness programs to reach more people with life-saving information about blood clots. Share your story with your local representatives and let your voice be heard. Your voice matters. Your story matters. Together we can Stop the Clot®. Get started now.
Reps. Axne, Burgess Raise Awareness for Blood Clots
Reps. Cindy Axne (IA-03) and Michael C. Burgess, M.D. (TX-26) introduced a resolution for Deep Vein Thrombosis and Pulmonary Embolism Awareness Month. Read the full news release here.
Senate Passes Resolution Recognizing DVT And Pulmonary Embolism Awareness Month
The National Blood Clot Alliance met with more than 30 Congressional offices this month, including Senators Chuck Grassley (R-Iowa) and Ben Ray Luján (D-N.M.), who introduced a Senate resolution recognizing the month of March as Deep Vein Thrombosis (DVT) and Pulmonary Embolism Awareness Month to help raise public awareness around this issue. On March 30, 2022, the resolution passed the Senate with unanimous support! Read the full news release here.
NBCA Virtual Fly In on Capital Hill
During March of 2022, the National Blood Clot Alliance “NBCA” completed a virtual fly in on Capital Hill, meeting with over 30 Congressional offices to bring much needed awareness about blood clots. Read more about this here.
Contact email@example.com for more information
CVS Caremark (part of CVS Health), has made changes to their 2022 commercial formulary which will reduce anticoagulant (blood thinner) choice for patients.
- Read more about what NBCA is doing to advocate for patients regarding this here.
- Supported by 14 cardiovascular patient and provider organizations, this letter outlines the concerning changes to the formulary, how non-medical switching endangers patients and compounds existing disparities and how reversing this ill-advised decision will protect at-risk patients.
- Say NO to non-medical switching. These decisions should be made by you and your doctor. Sign the pledge and add your voice to the thousands of patients impacted by this decision. Sign the pledge here.
- A message from our Communications Director, Beth Waldron, about non-medical switching: